Sanofi (SNY) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

This meeting is being recorded. Hello, everyone. This is Thomas Gussleisen from the Zenobia IRT. Welcome to the Q3 2025 Conference Call for Investors and Analysts. As usual, you can find the slides on zenobia.com. Please turn to slide number three. Here we have the usual forward-looking statements. We would like to remind you that information presented in this call contains forward-looking statements that are subject to substantial risk and uncertainty that may cause actual results to differ materially, we encourage you to read the disclaimer in our slide presentation. In addition, we refer you to our Form 20F on file with the US SEC and our French Universal Registration document for description of these risk factors. As usual, we'll be making comments on our performance using constant exchange rates and other non-IFRS measures. Numbers used are usually in millions of euros, and for Q3 2025, unless we state otherwise. Please turn to slide number four. First, we have the presentation, and then we take your questions. As usual, we aim at keeping it all to one hour, including questions. For Q&A, we have Olivier, Brian, and Thomas to cover our global businesses, as well as Roy, our general counsel, and Brendan, head of manufacturing and supply. And for the Q&A, you have two options in two. Raise your hand, submit your question using the Q&A function. With this, I hand you over to Paul and my guest, I'm sorry. Thomas. Thank you, everyone, for joining us today. Our growth momentum continued in Q3 with €12.4 billion in sales, up 7% over last year's high base of comparison. Sales growth was primarily driven by our new launches and the performance of DuPixent, which reached €4 billion in quarterly sales for the first time. After the third quarter performance, we're confident ...